ATE214596T1 - Feste zusammensetzungen mit einem nicht-amorphem wirkstoff und polyäthylenoxyd - Google Patents

Feste zusammensetzungen mit einem nicht-amorphem wirkstoff und polyäthylenoxyd

Info

Publication number
ATE214596T1
ATE214596T1 AT96913593T AT96913593T ATE214596T1 AT E214596 T1 ATE214596 T1 AT E214596T1 AT 96913593 T AT96913593 T AT 96913593T AT 96913593 T AT96913593 T AT 96913593T AT E214596 T1 ATE214596 T1 AT E214596T1
Authority
AT
Austria
Prior art keywords
active substance
compositions containing
polyethylene oxide
solid compositions
amorphous active
Prior art date
Application number
AT96913593T
Other languages
English (en)
Inventor
Pawan Seth
Andre Stamm
Original Assignee
Pharma Pass
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9478138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE214596(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharma Pass filed Critical Pharma Pass
Application granted granted Critical
Publication of ATE214596T1 publication Critical patent/ATE214596T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT96913593T 1995-04-14 1996-04-15 Feste zusammensetzungen mit einem nicht-amorphem wirkstoff und polyäthylenoxyd ATE214596T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9504520 1995-04-14
PCT/FR1996/000574 WO1996032097A1 (fr) 1995-04-14 1996-04-15 Compositions solides contenant du polyethyleneoxyde et un principe actif non amorphe

Publications (1)

Publication Number Publication Date
ATE214596T1 true ATE214596T1 (de) 2002-04-15

Family

ID=9478138

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96913593T ATE214596T1 (de) 1995-04-14 1996-04-15 Feste zusammensetzungen mit einem nicht-amorphem wirkstoff und polyäthylenoxyd

Country Status (6)

Country Link
EP (1) EP0830129B1 (de)
AT (1) ATE214596T1 (de)
AU (1) AU5652796A (de)
CA (1) CA2218054C (de)
DE (1) DE69619979T2 (de)
WO (1) WO1996032097A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
WO1998019708A2 (en) * 1996-11-04 1998-05-14 Union Carbide Chemicals & Plastics Technology Corporation Method for enhancing the solubility of substantially water-insoluble compounds
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
KR100545480B1 (ko) * 1997-06-06 2006-01-24 데포메드 인코퍼레이티드 매우 가용성인 약물의 제어방출을 위한 위체류성 경구약물제형
EP0998271B3 (de) * 1997-06-06 2014-10-29 Depomed, Inc. Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
EP0974343B1 (de) * 1998-07-22 2004-09-29 Pharma Pass II LLC Verfahren zur Herstellung einer festen Zubereitung enthaltend Metoprolol
HUP9902351A3 (en) * 1998-07-22 2001-01-29 Pharma Pass L L C Irvine Solid compositions containing metoprolol and process for producing the same
EP0987020A1 (de) * 1998-09-04 2000-03-22 Pharma Pass LLC Zusammensetzung enthaltend Metoprolol und Verfahren zur Herstellung
PT1205190E (pt) * 1999-08-04 2006-09-29 Astellas Pharma Inc Composicoes medicinais estaveis para uso oral utilizando oxidos de ferro
US20030157166A1 (en) * 2001-03-16 2003-08-21 Chen Chih Ming Controlled release sulfonylurea formulation
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20060147519A1 (en) * 2002-06-24 2006-07-06 Ashish Gogia Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US7442387B2 (en) * 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US8071119B2 (en) 2007-05-14 2011-12-06 Sustained Nano Systems Llc Controlled release implantable dispensing device and method
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US10166207B2 (en) 2013-06-05 2019-01-01 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
KR102810926B1 (ko) 2017-12-20 2025-05-22 퍼듀 퍼머 엘피 남용 억제 황산모르핀 제형

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US5273758A (en) * 1991-03-18 1993-12-28 Sandoz Ltd. Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms

Also Published As

Publication number Publication date
AU5652796A (en) 1996-10-30
CA2218054A1 (en) 1996-10-17
EP0830129B1 (de) 2002-03-20
DE69619979T2 (de) 2002-11-21
WO1996032097A1 (fr) 1996-10-17
CA2218054C (en) 2005-10-18
DE69619979D1 (de) 2002-04-25
EP0830129A1 (de) 1998-03-25

Similar Documents

Publication Publication Date Title
ATE214596T1 (de) Feste zusammensetzungen mit einem nicht-amorphem wirkstoff und polyäthylenoxyd
FI973828L (fi) Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi
ES2104797T3 (es) Composiciones farmaceuticas con actividad antagonista de angiotensina-ii.
FI911646A7 (fi) DTPA-monoamideja, näitä yhdisteitä sisältäviä farmaseuttisia aineita, niiden käyttö ja menetelmä niiden valmistamiseksi
ES2074846T3 (es) Nuevas naftil-etil-ureas y naftil-etil-tioureas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.
KR890700125A (ko) 신규 벤즈이미다졸 유도체, 그 제조방법 및 이 화합물을 함유하는 제약 조성물
HUT50786A (en) Process for producing new condensed heterocyclic compounds and pharmaceutical compositions containing them as active components
HUT41718A (en) Process for preparing phenyl-carbamates and pharmaceutical compositions containing such compounds as active substances
FR2559061B1 (fr) Compositions analgesiques et anti-inflammatoires contenant de la diphenhydramine
MY101791A (en) New benzimidazole derivatives
EP0783299A4 (de) Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe
FI934274A0 (fi) N-sulfonyl-2-oxi-indolderivat, deras framstaellning och dessa innehaollande farmaceutiska kompositioner
KR950701513A (ko) 화장용 필름 형성 조성물(cosmetic film forming compositions)
FI971536A0 (fi) Keratinosyytti-kasvutekijän analogeja
EA200000181A1 (ru) Фармацевтические композиции, содержащие витамин d и кальций, их приготовление и терапевтическое применение
SE8404065D0 (sv) Novel biologically active compounds
HUT38097A (en) Process for preparing substituted benzopyrans and pharmaceutical compositions containing them as active substances
IT1298338B1 (it) Composizioni farmaceutiche per l'ulcera
CA2077991A1 (en) Cosmetics and pharmaceuticals containing extensins and related methods
DE69613395D1 (de) Schwefelenthaltende di-ter-butylphenol-verbindungen brauchbar als entzündungshemmende mittel
SE8600658D0 (sv) Novel composition of matter
IL104485A0 (en) Benzimidazoles,their preparation and pharmaceutical compositions containing them
SE9403389D0 (sv) Pharmaceutical composition containing derivattves of sex hormones
MD970269A (en) Clavulanates
ATE66610T1 (de) Primycin enthaltendes kolloidales grundgel, verfahren zu dessen herstellung, dieses grundgel enthaltende pharmazeutische und pharmako- kosmetische kompositionen.